Arlington, Va.– The cell and gene therapy (CGT) industry is undergoing a transformative wave of financial activity, according to a new report released by Kalorama Information. The third edition of Cell and Gene Therapy Market Deals: Investments, M&As, and Partnerships, 2021–2025 provides an extensive analysis of the strategic transactions fueling one of the fastest-growing sectors in biotechnology.
Kalorama, a long-established provider of healthcare market intelligence, reveals that despite a tighter funding climate, the CGT market remained highly active through 2024. Investment in the space reached an estimated $39 billion last year, with a notable surge in the fourth quarter. The report analyzes over 2,000 CGT-related deals from the first quarter of 2021 through the end of 2024, highlighting a persistent trend toward collaborations, co-marketing, licensing, and supply chain partnerships.
Senior market analyst Justin Saeks emphasized the long-term momentum behind the sector, noting that even in the face of reduced venture funding compared to peak years, the appetite for innovation remains strong. “Many categories of deals, such as collaborations, distribution, and manufacturing partnerships, have shown consistent growth. There’s reason to be optimistic about continued investment in CGT,” Saeks said.
Major players driving deal activity include Astellas, Bristol Myers Squibb, Ginkgo Bioworks, Charles River, and Eli Lilly. The report also provides a global breakdown of deal activity, with analysis across North America, Europe, and the Asia-Pacific region.
Kalorama’s findings suggest that the cell and gene therapy ecosystem is becoming increasingly reliant on strategic partnerships to navigate shifting capital flows. In contrast to 2021’s peak funding year of $73 billion, investment levels fell to $35 billion by 2023. However, the number and diversity of deals continued to grow, indicating an evolution in how companies are financing growth and accessing new technologies.
The report is being released in two parts. The first installment, available now, covers activity through the end of 2024. A second update, covering through the third quarter of 2025, will be released this fall.
Kalorama’s report is positioned as a must-read for pharmaceutical executives, investors, business development professionals, consultants, and policy analysts seeking to understand funding trends, identify emerging opportunities, and benchmark against competitors in the CGT space.
With cell and gene therapies playing an increasingly vital role in next-generation medicine, the report underscores the importance of strategic dealmaking in shaping the future of this dynamic market. (Source: IANS)
